Amgen's bone drug denosumab beats Zometa in Phase III trial
15 July 2009
Asher Mullard
Please Login to read the full article.
15 July 2009
Asher Mullard
Amgen's next big drug hope, denosumab, was more effective than Novartis's Zometa (zoledronic acid) in a Phase III trial in breast cancer patients with bone metastases in delaying the time to the first skeletal related event (SRE; fracture, radiation to bone, surgery to bone or spinal...
Please Login to read the full article.
RELATED CONTENT
NEWS
- With questions raised on prostate cancer benefit, Amgen's Xgeva may face tough ODAC
- Japanese denosumab approval furthers Daiichi Sankyo's oncology ambitions
- What do promising prostate cancer drug results mean for Dendreon?
- Amgen fails to convince ODAC of Xgeva's benefit in prostate cancer
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
